PNPLA3 and autoimmune hepatitis: A significantly higher MELD score (P = 0.02, Fig. 3) among patients with pure AIH treated ≥ 6 months (n = 146) who carried at least one PNPLA3 p.148M risk allele was the only association between patients’ characteristics and the PNPLA3 variant at baseline.